impact factor
logo
 

Review

 

Epilepsy in systemic lupus erythematosus


1, 2, 3, 4, 5, 6

 

  1. Department of Paediatrics, University of L'Aquila, Italy.
  2. Department of Paediatrics, University of L'Aquila, Italy.
  3. Department of Paediatrics, University of L'Aquila, Italy.
  4. Department of Paediatrics, University of Chieti, Italy.
  5. Department of Immunorheumatology, University of L’Aquila, Italy.
  6. Department of Paediatrics, University of L'Aquila, Italy. alberto.verrottidipianella@univaq.it

CER13440
2021 Vol.39, N°3
PI 0651, PF 0659
Review

purchase article

PMID: 32896270 [PubMed]

Received: 12/04/2020
Accepted : 22/06/2020
In Press: 04/09/2020
Published: 21/05/2021

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune systemic disease characterised by a broad spectrum of clinical manifestations that may also affect the central nervous system. Among the neurological symptoms, seizures were included in the criteria for the classification of SLE published by EULAR/ACR in 2019. Several studies have been undertaken to explore the role of SLE antibodies in the onset of seizures, however, their complex relation is still a matter of debate. The most common seizure type reported is generalised tonic-clonic. EEG and MRI findings are usually non-specific; background slowing, brain atrophy and hyper-intense lesions on the white matter are the most common finding. Prognosis is overall favourable, with a good response to antiepileptic drugs and immunosuppressive therapy. The purpose of this review is to summarise the most relevant literature contributions published over the years on the epidemiology, aetiopathogenesis, clinical aspects, diagnosis and treatment of seizures in the context of SLE.

Rheumatology Article